Tactile Systems Technology (NASDAQ: TCMD) is one of 106 public companies in the “Surgical & medical instruments” industry, but how does it compare to its rivals? We will compare Tactile Systems Technology to similar companies based on the strength of its analyst recommendations, dividends, institutional ownership, profitability, valuation, earnings and risk.
Institutional & Insider Ownership
91.9% of Tactile Systems Technology shares are owned by institutional investors. Comparatively, 49.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 8.7% of Tactile Systems Technology shares are owned by insiders. Comparatively, 15.8% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
This table compares Tactile Systems Technology and its rivals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Tactile Systems Technology||6.29%||7.86%||6.56%|
|Tactile Systems Technology Competitors||-75.27%||-79.19%||-19.44%|
This is a breakdown of recent ratings and target prices for Tactile Systems Technology and its rivals, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Tactile Systems Technology||0||2||4||0||2.67|
|Tactile Systems Technology Competitors||538||1991||3889||135||2.55|
Tactile Systems Technology presently has a consensus price target of $41.13, indicating a potential downside of 11.48%. As a group, “Surgical & medical instruments” companies have a potential upside of 3.04%. Given Tactile Systems Technology’s rivals higher probable upside, analysts plainly believe Tactile Systems Technology has less favorable growth aspects than its rivals.
Risk & Volatility
Tactile Systems Technology has a beta of 0.39, meaning that its stock price is 61% less volatile than the S&P 500. Comparatively, Tactile Systems Technology’s rivals have a beta of 0.77, meaning that their average stock price is 23% less volatile than the S&P 500.
Earnings and Valuation
This table compares Tactile Systems Technology and its rivals revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Tactile Systems Technology||$109.28 million||$5.85 million||221.24|
|Tactile Systems Technology Competitors||$1.51 billion||$110.16 million||-201.24|
Tactile Systems Technology’s rivals have higher revenue and earnings than Tactile Systems Technology. Tactile Systems Technology is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.
Tactile Systems Technology beats its rivals on 7 of the 13 factors compared.
About Tactile Systems Technology
Tactile Systems Technology, Inc., a medical technology company, develops and provides medical devices for the treatment of chronic diseases in the United States. The company offers proprietary Flexitouch system, an at-home solution for lymphedema patients; and ACTitouch system, a home-based solution for chronic venous insufficiency patients. It also provides Entré System, a basic pneumatic compression device that is used for the at-home treatment of venous disorders, such as lymphedema and chronic venous insufficiency, including venous leg ulcers. The company was founded in 1995 and is headquartered in Minneapolis, Minnesota.
Receive News & Ratings for Tactile Systems Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tactile Systems Technology and related companies with MarketBeat.com's FREE daily email newsletter.